Lipopharma is a pioneering clinical-stage biopharmaceutical company that focuses its activities on the discovery, design and clinical development of a new generation of medicines that act through the selective regulation of membrane lipids, a novel therapeutic strategy known as “Membrane-Lipid Therapy” (MLT). Lipopharma arose as an academic spin-off, founded to turn new scientific breakthroughs and discoveries made by scientists at the Institute of Health Science Research (IUNICS - part of the University of the Balearic Islands in Mallorca, Spain) into a new class of innovative lipid-regulator therapeutic agents that we believe have dramatic game-changing potential in the treatment of life-threatening conditions like cancer, CNS, inflammatory or metabolic diseases
Palma de Mallorca, May 30, 2015. – Lipopharma announced today that updated results of the ongoing Phase I/IIA clinical trial with 2OHOA in patients with advanced solid tumours, including malignant glioma (MIN-001-1203), have been presented in a poster discussion session at the 51st annual meeting of the American Society of Clinical Oncology (ASCO), held in Chicago from the 29th of May to the 2nd of June, 2015.
Palma de Mallorca, April 07, 2015. – Lipopharma announced today that a key patent for the company, owned by the University of the Balearic Islands (UIB) and licensed in exclusive to Lipopharma, has been granted by the United States Patent and Trademark Office (USPTO). The patent has been published with number 9000042 and covers potential oncology indications of its lead product Minerval, currently being evaluated in a multicentre Phase I/IIa clinical study in patients with advanced solid tumours, including malignant glioma (MIN-001-1203).